Cannabidiol (10 and 20 mg/kg/d) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome: Results of a dose-ranging, multicenter, randomized, double-blind, placebo-controlled trial (GWPCARE2)
Ian Miller, M Scott Perry, Russell P Saneto, Ingrid Scheffer, Boudewijn Gunning, Rocio Sanchez-Carpintero, Antonio Gil-Nagel, Daniel Checketts, Lauren Whyte, Eduardo Dunayevich, Volker A Knappertz
NEUROLOGY | LIPPINCOTT WILLIAMS & WILKINS | Published : 2019
Awarded by GW Research Ltd
Study supported by: GW Research Ltd, operating in the United States through its affiliate, Greenwich Biosciences, Inc.; NCT02224703.